25 February 2010
Katie McQue
katie.mcque@informa.com
The EU's CHMP has concluded that Janssen-Cilag's (a Johnson & Johnson subsidiary) treatment for neuropathic skin ulcers in diabetic patients, Regranex (becaplermin), must not be used in patients who have any form of cancer as a precautionary measure.
The committee has also requested that...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Supreme Court takes another stab at refining US patent law
- FDA advisers back J&J-Bayer stroke drug, but call for warfarin transition testing
- EU reprieve for Actos as CHMP concludes benefits outweigh risks in selected patients
- Buflomedil falls off Loftyl perch and Celecoxib COX-2 as CHMP concludes reviews
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
